The first human antibody Adalimumab (Humira) using phage display technology was approved in USA in 2002 for the treatment of arthritis and Crohn’s disease which inactivates tumor necrosis factor-alpha (TNF-α) [9, 28]. Here, TNF is linked to Arthritis.